Wechselwirkungen · Retsevmo
Retsevmo 40 mg film-coated tablets Retsevmo 80 mg film-coated tablets Retsevmo 120 mg film-coated tablets Retsevmo 160 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 43
HOS-146882 · Präparat HOS-099572
Selpercatinib is a substrate for P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP) in vitro, however these transporters do not appear to limit the oral absorption of selpercatinib, as its oral bioavailability is 73% and its exposure was increased minimally by co-administration of the P-gp inhibitor rifampicin (increase of approximately 6.5% and 19% in selpercatinib AUC0-24 and Cmax, respectively).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-03T11:29:00Z · SHA-256 ea39918a3fb80726ed18974b1aa44d085db9e48e01020d5741da30903ff4eadc · Passage b52f5f63e678562978da51c3791e02405cb0ff438ec351bcde3564d045ca73a0 · Zeichen 244–660 im Abschnitt